Apg-2575
Refractory Leukemia
Institute of Hematology & Blood Diseases Hospital, ChinaPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Refractory Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Visilizumab The First Affiliated Hospital of Soochow University | Phase 3 | B |
cd123-car-nk cells Chongqing Precision Biotech Co., Ltd | Phase 1/2 | CCC |
Olverembatinib Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | CC |
Same molecule, other indications
Apg-2575 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →